89bio Inc. (ETNB)
| Bid | 7.85 |
| Market Cap | 1.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -462.14M |
| EPS (ttm) | -3.51 |
| PE Ratio (ttm) | -2.28 |
| Forward PE | -3.43 |
| Analyst | Buy |
| Ask | 8.45 |
| Volume | 1,987,938 |
| Avg. Volume (20D) | 2,348,277 |
| Open | 9.18 |
| Previous Close | 9.15 |
| Day's Range | 7.86 - 9.09 |
| 52-Week Range | 5.99 - 11.84 |
| Beta | 1.34 |
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorpor...
Analyst Forecast
According to 10 analyst ratings, the average rating for ETNB stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 262.27% from the latest price.
Stock Forecasts
3 weeks ago · https://thefly.com
89bio price target lowered by $8 at H.C. Wainwright, here's why13 Nov 29 Jan
1 month ago · seekingalpha.com
89bio's Pegozafermin Is Now Gaining Momentum89bio's Pegozafermin Is Now Gaining Momentum
2 months ago · seekingalpha.com
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 E...
